SUMMARY Four hundred and thirty-eight patients who had suffered a thromboembolic stroke not less than two weeks or more than four months previously, were entered into a placebo-controlled randomized clinical trial to determine whether suloctidil (200 mg t.i.d.) would influence the subsequent recurrence of stroke, the occurrence of myocardial infarction, or cardiovascular death.
A Secondary Prevention, Randomized Trial Of Suloctidil
SUMMARY Four hundred and thirty-eight patients who had suffered a thromboembolic stroke not less than two weeks or more than four months previously, were entered into a placebo-controlled randomized clinical trial to determine whether suloctidil (200 mg t.i.d.) would influence the subsequent recurrence of stroke, the occurrence of myocardial infarction, or cardiovascular death.
The two treatment groups were comparable at baseline with respect to important prognostic variables and there was good adherence to the study protocol during an average follow-up of 20 months. Significantly more patients complained of side-effects in the suloctidil group and more hepatotoxicity was also reported in the suloctidil group. Four cases of clinical hepatitis were suspected to be due to suloctidil, each of which was reversible on termination of study treatment; relative increases in SGOT and SGPT at three months in the suloctidil group were found to be mild and transient.
The primary analysis of efficacy was based on the incidence of the first event of stroke, myocardial infarction or cardiovascualr death, but excluding events that occurred more than 28 days after complete withdrawal from study medication for whatever reason. Thus, the primary analysis included 38 events in the suloctidil group and 47 in the placebo group (p = 0.17) representing a risk reduction of 24%. If total mortality is substituted for cardiovascular death, the corresponding figures are 47 in the suloctidil group and 58 in the placebo group (p = 0.08). There were interesting differences seen in an analysis of cardiovascular mortality alone (p = 0.06), and total mortality alone (p = 0.04), and specifically in terms of cardiac death where there were 15 deaths in the placebo group and only five in the suloctidil group. A total of 31 patients in the suloctidil group had a recurrence of stroke, fatal or non-fatal, compared with only 28 in the placebo group. As might be expected, the absolute differences in outcomes in the two treatment groups were similar, but statistically less impressive, when analyzed on an intention-to-treat basis.
Thus, there is no evidence of benefit of suloctidil in preventing the recurrence of stroke, but in view of the observed difference in cardiac death further studies with suloctidil may be warranted.
Stroke Vol 16, No 3, 1985 STROKE is the third most common cause of death in North America, being responsible for approximately 200,000 deaths each year. 1 It has been estimated that 40% die within a month of having a stroke 1 and the survivors remain at very high risk of cerebral or myocardial infarction or death. 2 There is evidence that the incidence of stroke is decreasing in developed countries' 4 and some of the recent trend is attributed to primary prevention in the form of efficacious treatment of arterial hypertension. 5 " 7 Secondary prevention has been based in part on surgery and the use of oral anticoagulants but the efficacy of these interventions has not been well demonstrated. 8 The majority of strokes are thromboembolic 2 9 and are sometimes preceded by transient ischemic attacks (TIA). l0 The established role of platelets in arterial thrombosis has, therefore, led to a number of randomized trials of platelet-inhibiting sulfinpyrazone 1 and ticlopidine 24 " 26 in patients with cerebral ischemia. There is evidence from the completed studies that aspirin (1 g/day) is, indeed, efficacious in patients with TIA's or very mild strokes in reducing the incidence of stroke or death; for the other three agents there is no real evidence of benefit. Studies with ticlopidine are still in progress.
However, the large majority of thromboembolic strokes are not preceded by TIA's; hence, only a small part of the problem has been addressed and the major question of prophylaxis for high risk survivors of a thromboembolic stroke remains unanswered. It is not appropriate to extrapolate the findings of the beneficial effect of aspirin to this patient population who are at the severe end of the spectrum of cerebral ischemia. Furthermore, aspirin, at the doses recommended, has significant side-effects and is not well tolerated by many patients. 27 For these reasons, we have carried out a randomized trial to assess the potential benefit of suloctidil, one of the newer platelet inhibiting agents, in reducing the incidence of further stroke, myocardial infarction or death in patients surviving a thromboembolic stroke. Suloctidil (l-(4-isopropylthiophenyl) -2-n-octylaminopropanol) is a vasoactive antiplatelet drug discovered in Belgium in 1971 by Continental Pharma. It is an antagonist of arterial vasospasm induced by different RANDOMIZED TRIAL OF SULOCTIDIL/G^i/ ei al agents; this action is mediated through inhibition of calcium influx. It inhibits spontaneous or induced platelet aggregation, in vitro as well as in vivo, by mechanisms not clearly understood but distinct from the non-steroidal anti-inflammatory agents such as aspirin. In different animal models, induced thrombi can be delayed or prevented by suloctidil. Finally, suloctidil does not affect the bleeding time or prothrombin time in man and does not interfere with anticoagulant therapy.
Patients and Methods Inclusion/Exclusion Criteria
To be considered for entry to the study, patients of either sex and any age had to have a neurologic deficit due to a well documented thromboembolic stroke in association with atherosclerosis no less than two weeks or more than four months prior to entry into the study. These included atherothrombotic strokes, lacunar infarctions and strokes that might have been due to emboli from the heart provided the patient was not on anticoagulant therapy. In every case, the deficit had to be present at the time of entry to the study.
From within this group were excluded those patients who 1. Had experienced no more than transient cerebral ischemia, a reversible ischemic neurological deficit or a mild thromboembolic stroke; 2. Had non-atherosclerotic conditions causing, or likely to cause, cerebral dysfunction, e.g. prosthetic heart valve; fibromuscular hyperplasia; arteritis; blood dyscrasia; other primary non-vascular brain disease such as Alzheimer's disease; 3. Had severe mental deterioration (i.e. Stage III dementia); 4. Were unsuitable for rehabilitation; 5. Had one or more of the following serious comorbid conditions: cancer (other than skin); uncontrolled congestive heart failure; severe hepatic or pulmonary disease; or (until remedied) renal failure (BUN > 50 mg%), diabetes (fasting blood sugar > 300 mg%), uncontrolled hypertension (diastolic pressure > 120 mg Hg); 6. Required treatment with aspirin, dipyridamole, sulfinpyrazone, indomethacin, chlorpromazine, tricyclic antidepressants or other antiplatelet agents, or were expected to require anticoagulants for more than six weeks post-randomization; 7. Lived too far from the collaborating clinical centre for adequate follow-up; 8. Were unwilling to give informed consent. The initial clinical assessment form for each patient entered into the study was reviewed by a Central Adjudicating Committee to ensure that the eligibility criteria had been met.
Initial Clinical Assessment
The neurological assessment at entry to the study included a comprehensive review of all available documentation relating to the qualifying stroke; cerebral angiography was optional but a CT scan report was mandatory. The initial clinical assessment also included a neurological examination, a neurological history, an assessment of functional status, a general medical history and an assessment of potential cardiovascular risk factors. An ECG and a chest x-ray were mandatory as was a standard battery of hematologic and blood chemistry laboratory evaluations.
Follow-Up
Patients were followed at three months and then every three months thereafter for up to three years. At each follow-up visit, neurological and cardiovascular examinations were repeated, compliance and contamination were evaluated and a routine search made for possible toxicity and side-effects of treatment. Appropriate laboratory tests were carried out, electrocardiograms and chest x-ray films were obtained at the end of the study and when clinically indicated.
All significant outcome events were reported on specially designed forms and as much supporting documentation obtained as possible.
While it was recognized that a number of patients would not complete the study according to the protocol and that they or their physicians would be unwilling on occasion to have them continue with the prescribed study medication, the policy of the study was that patients would be withdrawn completely and permanently from study medication only for alleged serious adverse reactions to study treatment or for death. Those patients who withdrew completely and permanently from study medication, for whatever reason, were continued to be followed as carefully as possible until death or until the close of the study, and significant clinical outcome events recorded. The vital status of all but two patients was known at the end of the study.
Treatment Regimens and Allocation
The two treatment regimens to be compared comprised a 200 mg capsule of suloctidil or a matching placebo capsule to be taken three times daily.
Eligible patients were allocated to one of these two regimens according to randomization lists prepared separately for each of the four collaborating centres; within each centre, patients were further stratified for sex and type of qualifying stroke (atherothrombotic, cardiac-embolic or lacunar infarction).
The active drug and placebo capsules were identical in size, shape, weight and colour and were distributed from the Coordinating Centre to the respective clinical centres in identical bottles, each containing 300 capsules. At any one time, each clinical centre had a small stock of bottles on hand labelled with random threedigit numbers and the centre was required to contact the Coordinating Centre at the time of randomization to identify which bottle was to be issued to the patient. Bottles of medication with that patient's name and study I.D. number were later sent to the clinical centre for subsequent follow-up visits. This scheme allowed the study to be executed without either the patients or the study clinicians being aware of which treatment regimen a patient was being allocated to. This is also an efficient scheme in that it minimises the storage and possible wastage of study medications in each centre.
Outcome Events
The cluster of outcomes on which the primary assessment of efficacy was based was the recurrence of stroke or occurrence of myocardial infarction or cardiovascular death. Criteria for each of these events were established and applied consistently by the Central Adjudicating Committee without knowledge of which test treatment particular patients were taking. Each of the three members of this committee made an independent assessment of each outcome event and any initial disagreements were then resolved by discussion and consensus.
Unlike the qualifying stroke which had to be thromboembolic, the outcome event of stroke also included stroke due to hemorrhage. The criteria for myocardial infarction included at least two of (1) typical chest pain, (2) compatible ECG changes or a myocardial scan, and (3) appropriate serum enzyme elevations. Death was categorized as stroke death, cardiac death, or death due to other causes, the first two combining to form cardiovascular death. Deaths attributed to pneumonia which had clearly been precipitated by a specific cardiac or cerebrovascular event were classified as cardiovascular deaths. The severity of a stroke outcome event was graded as mild (either neurological symptoms or signs present but no impairment of activity), moderate (both neurological symptoms and signs present and impairment of activity in no more than one of speech, arm or leg) and severe (both neurological symptoms and signs present and impairment of activity in at least two of speech, arm and leg).
Alleged adverse reactions of study treatments were carefully elicited during the course of the study and documented with as much detail as possible.
Statistical Methods
To take into account the staggered times of entry of patients into the study and the variable times for which individual patients were followed up, survival curves were calculated using the Kaplan-Meier approach and overall comparisons made between the outcomes in the two treatment groups using the Mantel-Haenszel test statistic. 28 Estimates of relative risk reduction were derived from the Cox proportional hazard model. 29 The primary analysis of efficacy was based on the composite outcome of recurrence of non-fatal stroke, occurrence of non-fatal myocardial infarction or cardiovascular death; for this composite cardiovascular outcome, the analysis was based on the first event. Analyses based on this cluster of events but including death from any cause was also planned as were analyses based on cardiovascular death alone, on death from any cause and for stroke or stroke death. These secondary analyses should be interpreted with some caution since the true significance levels are affected by the repeated analysis of the data.
Following the methodological arguments of Gent and Sackett, 30 -31 it was planned from the start to exclude from the main analyses patients who were randomized but ruled subsequently to be ineligible by the Central Adjudicating Committee. It was also planned to exclude from the main analyses all subsequent events in patients who permanently terminated study medication. However, since a threatened cardiovascular or cerebrovascular event could, in itself, be the cause of treatment withdrawal, a "28 day rule" was adopted in which patients were considered still to be at risk for a period of 28 days following the decision by the patient and/or physician to stop study medication permanently. Any events that occurred during this 28 day period were charged against the study treatment to which the patient had been randomly allocated.
Since both post-randomization patient eligibility decisions and the "28 day rule" were applied blindly with respect to treatment allocation, no bias was expected to result from these strategies and a considerable potential gain in statistical sensitivity achieved. Nevertheless, full disclosure of additional events in ineligible randomized patients and in post "28 day" periods have been provided in this report of the study.
Appropriate parametric tests of significance were carried out to analyze baseline characteristics in order to assess the initial comparability of the patients in the two treatment groups. Important imbalances in these baseline characteristics were adjusted for in the overall assessment of the possible benefit of suloctidil using the Cox proportional hazard model. 29 
Feasibility
At the time of planning this study, there was a good deal of information about factors related to the risk of developing complications of vascular disease, including stroke, but information was meagre regarding risk for subsequent stroke or death after recovery from a thromboembolic stroke. Thus, the estimates of the mortality rate or the incidence of recurrent stroke or myocardial infarction were relatively imprecise but from a critical review of the literature an overall estimate of a rate of 30% over two years for one or more of these outcomes seemed reasonable. 21 It was then calculated that we would need to include 320 patients in each treatment group, and follow them for two years, if we were to have a 90% chance (/3 = 0.10) of detecting a statistically significant difference (a = 0.05) if the true benefit of suloctidil was a reduction to 20% in the rate of these outcomes. Four centres collaborated in this study and it was anticipated that the required number of patients would be accrued over a three year period and the study was planned to close at the end of the fourth year.
No formal stopping rule procedures were established, but it was planned to analyse the available data for efficacy and safety at the end of three years before making a final decision to discontinue entry of patients into the study.
Results

Patient Enrollment
Patients were entered into the study from four clinical centres in Hamilton, London, Toronto and Montreal between September, 1979 and December, 1982 and follow-up of patients was completed by July, 1983.
A total of 447 patients were enrolled of which nine were ruled ineligible by the Central Adjudicating Committee; of these, five patients were randomized but refused to give informed consent and never received study medication, two died from their qualifying stroke soon after randomization, one had Alzheimer's disease and one had had a hemorrhagic rather than a thromboembolic stroke. These latter two cases were on study treatment for only a short time. Five of these nine ineligible patients were in the placebo group, all of whom died before the end of the study, and four were in the suloctidil group, two of whom died before the end of the study.
Patient Characteristics at Entry
Of the remaining 438 patients on whom the evaluation of the efficacy and safety of suloctidil is based, 218 were in the suloctidil group and 220 in the placebo group; the average duration of follow-up was 20 months in each treatment group.
The baseline demographic and clinical characteristics of the two groups are summarized in tables 1-3. The two groups can be seen to be comparable with respect to sex, age, smoking history, cardiovascular comorbidity, the characteristics of the qualifying stroke and cerebrovascular history. Among these various characteristics it should be noted that the study group was 60% male, 67 years of age on average, and with significant cardiovascular comorbidity; only 21 % had a history of TIA's, for 82% of cases the qualifying stroke was their first and for 82% the qualifying stroke was atherothrombotic.
Adherence to Protocol
Compliance with the prescribed treatment regimens was assessed at each scheduled follow-up visit by a simple pill count of the medication returned. If reasonable compliance is defined as (a) returning the pills at the follow-up visit and (b) having apparently taken at least 70% of the recommended amount since the last visit, then compliance in the suloctidii group averaged 75% over the course of the study compared with 79% in the placebo group; compliance in both groups was fairly constant over the course of the study. Among those returning their unused pills at follow-up visits, the mean percentage of prescribed medication taken was 91 % in the suloctidil group and 92% in the placebo group; again, this rate was constant over the duration of the study in each treatment group. The number of patients withdrawing completely from study medication before the end of the study, for any reason other than death, was 71 (33%) in the suloctidil group and 67 (31%) in the placebo group. The primary reasons for such withdrawals are summarised in table 4. It can be seen that the numbers withdrawing for the various reasons were similar in the two groups, except with respect to side effects.
Side Effects of the Study Treatments
The number of patients reporting any side-effects at any time during the course of the study was 67 (31%) in the suloctidil group and 29 (13%) in the placebo group; this difference is statistically highly significant (p < 0.001). Alleged side-effects were sufficiently severe, troublesome or numerous to cause complete withdrawal from study treatment in 29 patients in the suloctidil group and 12 patients in the placebo group; again this difference is statistically significant (p = 0.01). The principal reasons for such withdrawals are summarized in table 5 from which it can be seen that the most striking differences against the active treatment are for vertigo/dizziness (5 v 0), constipation (4 v 0) and suspected hepatitis (6 v 1).
The latter adverse reaction is potentially the most serious. A careful review of the charts of every patient in the study was subsequently carried out which disclosed two additional cases, both on placebo, for whom the word jaundice or hepatitis appeared in the patient record.
The complete charts for each of these nine cases of suspected drug-related hepatitis were reviewed carefully, and without knowledge of study treatment, by a gastroenterologist (S.M.C.). The conclusions reached by this independent reviewer were that study druginduced hepatitis was unlikely in one case on placebo, and most unlikely in the other two cases on placebo. For the six cases on suloctidil, the corresponding conclusions were that it was unlikely to be study drug related in one case, extremely unlikely in another case, suggestive in one case and highly suggestive in the Suloctidil Placebo other three cases. No cases were rechallenged with the study drug and in every case the hepatitis was reversible when the study treatment was terminated.
In view of this suspected hepatotoxicity, a detailed analysis of liver enzyme data was carried out. This revealed evidence of a relative increase in SGOT and SGPT at three months in the suloctidil group. However, these increases were mild, transient and values invariably returned to normal even when the patient continued on study treatment. Even among 37 cases with elevated SGOT and/or SGPT at baseline there was no evidence of any consistent effect of suloctidil at the three month assessment; 10/15 (66%) on placebo had normal transaminase values at three months, as had 15/22 (60%) on suloctidil. Only one of the 37 cases with elevated SGOT and/or SGPT subsequently developed clinical hepatitis. Therefore, elevated transaminases on entry into the study did not predict the development of clinical hepatitis or transaminasemia.
A considerable amount of laboratory data was collected and, for the purpose of assessing possible adverse effects of study treatment, "action" values were defined for a number of laboratory measures; these were values beyond which it was believed most clinicians would consider withdrawing study treatment. A number of these values are summarized in table 6 and it can be seen that the results were similar in the two treatment groups with the exception of SGOT for cases on suloctidil two were classified as clinical hepatitis.
Primary Analysis of Efficacy
The primary analysis of efficacy was based on the incidence of the first event of recurrence of stroke, occurrence of myocardial infarction or cardiovascular death, but excluding events that occurred more than 28 days after complete withdrawal from study medication. Thus, the primary analysis included 38 events in the suloctidil group compared to 47 in the placebo group (See tables 7 and 8). The proportions of patients in the two groups remaining event-free at different times over the three year period of follow-up are shown in figure 1 . It can be seen that the two curves are very close to each other during the first two years of follow-up and diverge only during the third year; life table analysis using the Mantel-Haenszel method to compare these two curves gave a/?-value of 0.17 (table  8) . Adjustments for imbalances between the two treatment groups in baseline characteristics had almost no effect on this p-value.
The estimated benefit of suloctidil was a risk reduction of 24% with the 95 per cent confidence limits ranging from a 50% risk reduction to a 17% risk increase.
It may be recalled that the expected rate of events in the control group was estimated to be 30% when planning the study; the observed rate in the placebo group was 27%.
Analyses of Efficacy Using Other Outcome Events
In a secondary analysis based on the incidence of the first event of stroke, myocardiai infarction or death from any cause, but still excluding events that occurred more than 28 days after complete withdrawal from study medication, there were 47 such events in the suloctidil group compared to 58 in the placebo group (see tables 7 and 8). The proportion remaining eventfree in each treatment group is shown in figure 2 ; there is a consistent observed benefit favoring suloctidil which is not statistically significant (p = 0.08). Once again the .estimated benefit of suloctidil was a risk reduction of 24% with the 95 per cent confidence limits ranging from a 48% risk reduction to a 12% risk increase.
Ignoring non-fatal events and analyzing only deaths, it can be seen from tables 8 and 9 that there were 10 cardiovascular deaths in the suloctidil group and 18 in the placebo group (p = 0.06); the corresponding total mortality figures were 21 and 29 and this difference is statistically significant (p = 0.04). These p-values are somewhat more impressive than might be suggested by the observed differences in the number of deaths but it must be remembered that they are based on life table analyses which take into account not only the number of deaths but also when they occurred. Adjustment for important baseline characteristics tended to reduce the estimated treatment effect slightly.
The observed difference in deaths between the two treatment groups was essentially in cardiac death, there being only five in the suloctidil group compared with 15 in the placebo group. During the review of outcome events by the Central Adjudicating Committee, these deaths had been classified as MI, sudden death or other cardiac before being collectively classified as cardiac deaths. The distribution of deaths within these subclasses were respectively 1,3 and I in the suloctidil group and 3,8 and 4 in the placebo group. Since these patients were selected for study because they had had a thromboembolic stroke it is also pertinent to assess the effect of suloctidil on the recurrence of major cerebrovascular events only. There were 31 patients in the suloctidil group who had a recurrence of stroke, fatal or non-fatal, compared to 28 patients in the placebo group; the corresponding figures for fatal stroke only were five and three, respectively. Of these 59 first recurrences of stroke, 50 were atherothrombotic, four were cerebral emboli, four were lacunar, and one was hemorrhagic. In classifying the severity of the stroke as mild, moderate or severe there were respectively 7, 10 and 14 cases in the suloctidil group compared with 6, 13 and 9 cases in the placebo group. Hence, there is no evidence of any real benefit of suloctidil in preventing the recurrence of stroke or in reducing its severity.
Fifty nine patients (13%) suffered a cerebral infarction during a mean follow-up of 20 months; of these, 8 (14%) died from their stroke.
Analyses on an Intention-To-Treat Basis
If one ignores the 28-day qualification and counts any events that occurred during the course of the study, Discussion It has been suggested that drugs which suppress platelet function might improve prognosis in patients with diseases thought to be associated with platelet thrombi. Two such disorders are cardiac disease and cerebrovascular disease; these are major causes of morbidity and death and are, therefore, particularly important disorders in which to study the possible benefits of platelet-inhibiting drugs.
There have been several studies of platelet-inhibiting drugs in cardiac disease. Promising results in secondary prevention studies in patients who survived an MI have been reported with aspirin by Elwood et al, 37 -38 the Coronary Drug Project Research Group, 39 Breddin et al, 40 44 both reported significant benefits of sulfinpyrazone on cardiac outcomes. Striking reductions in MI or cardiac death with the use of aspirin in patients with unstable angina have been reported by Lewis et al 45 and Cairns et al. 46 The first published controlled clinical trial in cerebrovascular disease was that of Acheson et al who were not able to demonstrate any benefit of dipyridamole in 169 patients with established cerebrovascular disease. 20 In a subsequent study Acheson and Hutchinson could show no real benefit of clofibrate in a similar group of patients. 19 Blakely and Gent 21 studied a heterogeneous group of elderly patients and among those who had previously had a stroke, observed a significant reduction in the two-year mortality in the sulfinpyrazone treated group (17%) compared to the placebo group (35%). Evans showed a significant benefit of sulfinpyrazone in twenty patients with transient blindness but only in terms of short-term relief of symptoms. 23 Large scale trials by Fields 14 and the Canadian Co-operative Study Group 12 showed a benefit of aspi-. 18 reported no statistically significant reduction in stroke or death in patients with TIA who were treated with aspirin. However, it has been pointed out that this study had a rather low statistical power due to the small number of patients studied. 47 The majority of patients included in the above studies of cerebrovascular disease had only transient cerebral ischemia with some cases of mild strokes being included. The exception was the study by Bousser et al in which the majority of patients had had a stroke, all of which were mild. Given that the large majority of thromboembolic strokes are not preceded by TIA's and that patients who survive a thromboembolic stroke are at high risk of recurrence of stroke, the occurrence of myocardial infarction or cardiovascular death, we selected this population to study the possible benefit of suloctidil in reducing the incidence of these cardiovascular events.
The findings from this study are promising but inconclusive. Our primary analysis showed an observed risk reduction of 24 per cent in the cluster of cardiovascular events which, if real, is clearly clinically important but which is not statistically significant. Indeed, the 95 per cent confidence limits on this estimate suggest that the benefit could be as high as a 50% risk reduction (or as bad as a 17% risk increase). If, in fact, the intended recruitment of 640 patients had been achieved, and the same risk reduction observed, then it would have been statistically, as well as clinically significant.
As in most studies, the actual rate of recruitment was less than had been anticipated so that when we did our planned analysis at the end of three years there were only 380 patients on whom we had at least a three month follow-up assessment. Analyses of these data were carried out similar to those reported for the completed study and at that time there was no observed benefit of suloctidil at all with respect to either of the two main clusters of outcome events; indeed, the observed differences at that time favoured the placebo group. Concurrently, there was also increasing concern about the possible hepatoxicity of suloctidil. After full discussion among the group of investigators it was decided to stop entering patients because of the lack of observed benefit and the possible toxicity and to simply follow the existing cohort for a further six months before terminating the study.
The adverse hepatic effects reported in this trial with suloctidil, at a dose of 600 mg daily, were unexpected since neither the animal toxicology data nor the reported clinical experience had suggested this possibility. Clinically manifest hepatitis was first reported in a trial exploring a 1200 mg daily dose of suloctidil in type II hyperlipemic patients. 48 More recently a few cases of icteric hepatitis have been reported from France in association with the use of suloctidil at doses of 300-500 mg daily. In our experience, abnormal baseline transaminase serum levels did not predispose to clinical hepatitis, and the cases of hepatitis observed reversed when the drug was discontinued.
The addition of another 60 patients together with the further follow-up of the cohort included in the interim analysis led to a significant increase in the total number of patient years of study and a corresponding increase in the number of observed outcome events. The number of new events in the suloctidil group was appreciably lower than in the placebo group and this is reflected in the final observed difference in favour of suloctidil, where none had existed in the interim analysis. The exclusion of events suffered some time after termination of study treatment is controversial.
30 3I The intention is to make the assessment of efficacy more sensitive by ruling out events which are thought unlikely to have been influenced by study treatment. If this strategy is unbiased then the number of events excluded from the efficacy analyses should be similar in the two treatment groups. As can be seen from tables 7 and 9 the number of such events is, indeed, similar in the two treatment groups.
Thep-values associated with the secondary analyses should be interpreted with some caution since the possibility of spurious statistical significance increases with the number of questions asked of the data. There is no real evidence to suggest that suloctidil is likely to reduce the recurrence of severity of stroke and it is in cardiac death, 5 v 15, where the observed benefit of suloctidil lies. However, it must be borne in mind that the number of cardiac deaths is small and the observed differences should be viewed only as an interesting, unexpected finding.
Among possible future studies to assess this potential benefit of suloctidil in reducing cardiac death would be in the secondary prevention of myocardial infarction, either against beta-blockers, or against a placebo control in patients who are unsuitable for betablockers. Another high risk group might be patients requiring but ruled unsuitable for coronary bypass surgery. These new studies would need to be very large and would require considerable resources.
